Acute Myeloid Leukemia

Ceplene receives orphan drug designation in Europe for AML

Published in Cancer Weekly, April 5th, 2005

Maxim Pharmaceuticals, Inc., (MAXM)) announced that Ceplene (histamine dihydrochloride) was granted orphan drug designation by the European Commission (EC) for the treatment of acute myeloid leukemia (AML) patients following adoption of a positive opinion by the Committee for Orphan Medicinal Products of the European Agency for the Evaluation of Medicinal Products.

Orphan drug status is granted by the EC to promote development of drugs to treat rare diseases or conditions. Orphan drug designation in the European Union may provide several benefits, including 10 years' marketing exclusivity throughout Europe for the therapeutic indication for which it was granted,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-04-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry